SYRE FY 2025 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$172M

Operating Income

-$210M

Net Income

-$155M

EPS (Diluted)

$-1.98

Cash Flow

Operating Cash Flow

-$169M

Free Cash Flow

-$169M

Stock-Based Comp.

$38M

Balance Sheet

Total Assets

$778M

Total Liabilities

$63M

Stockholders' Equity

$715M

Cash & Equivalents

$86M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$172M	$0	—
Operating Income	-$210M	-$209M	-0.5%
Net Income	-$155M	-$208M	+25.4%